Geneoscopy Closes $105M In Financing To Advance Its Noninvasive Multifactor Rna Screening Test For Colorectal Cancer Prevention
PRIVATENov 16, 2021
Amount Raised
$105 Million
Round Type
Funding Round
St. LouisBiotechnologyHealthcareHealth CareTherapeuticsHealth Diagnostics
Description
Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal health, today announced the closing of a Series B financing, raising a total of $105 million through a combination of debt and equity. The round is led by previous investors Lightchain Capital and NT Investments. Other investors in the round include Morningside Ventures, Labcorp, Cultivation Capital, BioGenerator Ventures, and Innovatus Capital Partners.
Company Information
Company
Geneoscopy
Location
2220 WELSCH INDUSTRIAL CT.
St. Louis, Missouri, United States
About
Geneoscopy is a life sciences company with the mission to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Geneoscopy’s lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded a Breakthrough Device Designation from the FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Our initial prospective clinical study demonstrates that the diagnostic can detect these lesions with greater sensitivity than all existing noninvasive screening tests, thereby, serve as a potential aid in early detection and prevention of cancer. Geneoscopy is also developing diagnostics for the diagnosis and management of inflammatory bowel disease in partnership with biopharmaceutical companies and leading academic research institutions.
Fundz sees it the moment Geneoscopy raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
St. LouisBiotechnologyHealthcareHealth CareTherapeuticsHealth Diagnostics